Chris Carpenter

Dr. Chris Carpenter is a medical oncologist and the current Chief Medical Officer at Rubius Therapeutics. Chris has over 25 years of experience in the pharmaceutical and biotechnology industries. Prior to joining Rubius, they served as the Chief Medical Officer at Catamaran Bio from April 2020 to April 2022. Before that, they were the Chief Medical Officer at Rubius Therapeutics from September 2017 to March 2020.

Dr. Carpenter began their career as an Assistant/Associate Professor of Medicine at Harvard Medical School from September 1996 to June 2007. Chris then moved into the pharmaceutical industry, joining GlaxoSmithKline (GSK) in November 2013 as the VP/SVP of Cancer Epigenetics DPU Head. Chris remained with GSK until September 2017, when they became the Chief Medical Officer at Rubius Therapeutics.

At each company, Dr. Carpenter has played a vital role in developing new treatments and therapies for cancer patients. Chris has also been a leader in clinical development and governance, biomarker development, and clinical oncology. In addition, they have served as a consultant for several companies from April 2020 to March 2022.

Dr. Carpenter is a highly respected oncologist who has dedicated their career to helping cancer patients receive the best possible care. Chris is a talented physician and researcher who has made significant contributions to the field of oncology.

Chris Carpenter's educational career includes a Bachelor of Science in Biology from Stanford University and a Doctor of Medicine and Doctor of Philosophy in Pharmacology from USC.

Some of their coworkers include Tom Wickham - Vice President, Research and Development, Avak Kahvejian - Co-Founder and Chief Innovation Officer, and Nathan Dowden - Senior Vice President, Corporate Development. Chris Carpenter reports to Torben Straight Nissen, President.